Another phase I/II study is studying single-agent zenocutuzumab (MCLA-128) in patients with solid tumors, including NSCLC and pancreatic cancer, harboring an NRG1 fusion. This evidence concerns the gene NRG1 and familial pancreatic carcinoma.